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Background: Chemoradiotherapy (CRT) including three cycles of cisplatin is considered
the standard of care for locally advanced head and neck squamous cell carcinoma
(LA-HNSCC). However, around one-third of the patients cannot complete cisplatin
because of toxicity. Carboplatin plus 5-fluorouracil (carbo-5FU) is another accepted
treatment option with a different toxicity profile. We compared tolerability and efficacy
of concomitant carbo-5FU and cisplatin.
Patients and Methods: We conducted a retrospective analysis of LA-HNSCC patients
treated with CRT in two Dutch cancer centers between 2007 and 2016. All patients
received intensity-modulated radiotherapy. One center routinely administered carboplatin
300–350 mg/m2 at day 1, 22, and 43 followed by 5FU 600 mg/m2/day for 96 h. The
other center used cisplatin 100 mg/m2 at day 1, 22, and 43. The primary endpoint of this
study was chemotherapy completion rate. Secondary endpoints included overall survival
(OS), disease-free survival (DFS), locoregional control (LRC) and distant metastasis–free
interval (DMFS), toxicity, and unplanned admissions.
Results: In the carbo-5FU cohort (n = 211), 60.2% of the patients completed
chemotherapy vs. 76.7% (p < 0.001) of the patients in the cisplatin cohort (n = 223).
Univariate analysis showed a higher risk of death in the carbo-5FU cohort [hazard ratio
(HR) 1.53, 95% CI, 1.09–2.14, p = 0.01] with a 3-year OS of 65.4 vs. 76.5% for
cisplatin. OS was independently associated with T and N stage and p16 status, but
not with chemotherapy regimen (HR 1.08, 95% CI, 0.76–1.55, p = 0.65). Three-year
DFS was 70.0% for carbo-5FU vs. 78.6% for cisplatin (HR 1.37, 95% CI, 0.93–2.01,
p = 0.05). A similar outcome was observed for both LRC (HR 1.27, 95% CI, 0.74–2.09,
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p = 0.4) and DMFS (HR 1.08, 95% CI 0.62–1.90, p = 0.77). The risk of discontinuation
for chemotherapy-associated toxicity was higher in the carbo-5FU cohort than in the
cisplatin cohort (relative risk = 1.69).
Conclusion: LA-HNSCC patients treated with concomitant carbo-5FU completed
chemotherapy less frequently than patients treated with cisplatin. Treatment regimen was
not an independent prognostic factor for OS.
Keywords: area under the concentration–time curve, carboplatin 5-flourouracil, chemoradiotherapy, cisplatin,
comparison, head and neck squamous cell carcinoma, locally advanced head and neck squamous cell carcinoma
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is the seventh
most common type of cancer worldwide, accounting for 600,000
new cases and 250,000 cancer deaths each year (1, 2). About
half of the patients are diagnosed with locally advanced head
and neck squamous cell carcinoma (LA-HNSCC) (3). Definitive
chemoradiotherapy (CRT) is the treatment of choice in patients
with unresectable LA-HNSCC. Concomitant CRT has been
shown to be superior to radiotherapy alone, with an absolute
survival benefit of 6.5% at 5 years, raising 5-year overall survival
(OS) from 27.2 to 33.7% (4). In addition, recent studies have
indicated that higher cumulative cisplatin dose is associated with
better OS (5, 6).
Concomitant CRT consisting of three cycles of high-dose
cisplatin on day 1, day 22, and day 43 in combination with
70 Gray (Gy) radiotherapy in 35 fractions is considered the
standard of care. However, this regimen causes significant
acute and late toxicity. As a result, approximately one-third
of the patients cannot complete three cisplatin cycles (7).
Concomitant carboplatin plus 5-fluorouracil (carbo-5FU) has
also been shown to improve OS compared to radiotherapy
alone and is an accepted treatment regimen (4). However, no
randomized controlled trials comparing concomitant cisplatin
with concomitant carbo-5FU have been conducted. To study
differences in tolerability and efficacy of both regimens, we
compared all consecutive patients from one Dutch cancer center
that routinely used carbo-5FU with all consecutive patients
from another Dutch cancer center that routinely used high-
dose cisplatin.
We hypothesized that carbo-5FU is better tolerated than
cisplatin and will be reflected by a higher percentage of
patients completing three chemotherapy cycles, with similar
efficacy. Therefore, the primary endpoint of this study was
chemotherapy completion rate. Secondary endpoints included
OS, disease-free survival (DFS), locoregional control (LRC) and
distant metastasis–free interval, toxicity, and the number of
unplanned admissions.
PATIENTS AND METHODS
Patients, Study Design, and Data
Collection
We conducted a comparative retrospective cohort study of
patients who received primary concomitant CRT for LA-
HNSCC at the University Medical Center Groningen (UMCG)
or Amsterdam University Medical Center (AUMC) between July
2007 and February 2016. Inclusion criteria were histologically
proven HNSCC, stage III–IVB and concomitant CRT as primary
treatment. Patients with nasopharyngeal carcinoma and patients
who received postoperative CRT or CRT for cancer recurrence
were excluded. Chemotherapy other than carbo-5FU (UMCG) or
3-weekly cisplatin (AUMC) was an additional exclusion criterion.
Both centers prospectively included all patients treated with CRT
in a database; these databases were used to identify candidates
for both cohorts. Information about patient demographics,
comorbidity, smoking, tumor characteristics, treatment details,
toxicity, and outcome were extracted from electronic patient
records. Survival status of patients lost to follow-up was checked
in the population register. TheDutchMedical Research Involving
Human Subjects Act does not apply to data collection as part
of routine clinical practice. Therefore, the local ethics committee
determined that this study was exempt from the ethical approval
requirement. The study was registered at ClinicalTrials.gov
(Identifier: NCT02778191).
Endpoints
The primary endpoint of the study was the percentage of
patients completing three chemotherapy cycles, regardless of
dose reduction. Secondary endpoints included overall OS, DFS,
LRC and distant metastasis–free interval, toxicity, and the
number of unplanned admissions. OS was defined as the time
between diagnosis and death from any cause. Patients who were
alive at the last follow-up were censored. DFS was defined as the
time between the last day of CRT and first evidence of relapse
or death from any cause, whichever occurred first. LRC was
defined as the time between the last day of CRT and first evidence
of local or regional relapse. Distant metastases–free interval
was defined as the time between the last day of CRT and first
evidence of distant metastasis. For LRC and distant metastasis–
free interval, patients who died without evidence of recurrence
were censored at the date of death. Toxicity was reported
according to CTCAE version 4.03. Reasons for chemotherapy
discontinuation were noted.
Treatment Regimens
The carbo-5FU regimen consisted of carboplatin 300 mg/m2 for
patients with a creatinine clearance of 80–120 mL/min and 350
mg/m2 for patients with a creatinine clearance of >120 mL/min.
Creatinine clearance was calculated using the Cockcroft–Gault
formula. Carboplatin was given intravenously in 250mL of
dextrose 5% over 30min. 5FU was given as a continuous infusion
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at a dose of 600 mg/m2/day in 2,000mL of normal saline with
20 mmol potassium for 96 h. The whole chemotherapy cycle
was given as an inpatient regimen. Chemotherapy cycles were
started on day 1, day 22, and day 43 of radiotherapy. Cisplatin
100 mg/m2 was given intravenously in 500mL of normal saline
over 3 h on day 1, day 22, and day 43 of RT. Prehydration
consisted of 1 L of normal saline plus 20 mmol potassium and
2 g of magnesium sulfate over 2 h and posthydration consisted
of 4 L of normal saline plus 80 mmol of potassium and 8 g
of magnesium sulfate over 20 h. Dexamethasone and a 5-
HT3 receptor antagonist were given as antiemetics with both
treatment regimens; and patients treated with cisplatin also
received aprepitant. All patients received intensity modulated
radiotherapy with 70Gy in 35 daily fractions of 2Gy on weekdays
on the primary tumor and involved lymph nodes. Elective areas
were treated with 54.25Gy in 35 daily fractions of 1.55 Gy.
Clinical Evaluation and Follow-Up
During treatment, patients were evaluated weekly by a radiation
oncologist for locoregional toxicity. In addition, patients were
evaluated by a medical oncologist before and after every
chemotherapy cycle for systemic toxicity until resolution of acute
side effects. Response evaluation, including clinical examination
and computerized tomography (CT) or magnetic resonance
imaging (MRI), was performed 8–12 weeks after CRT. In case
of residual disease, salvage surgery was performed if possible.
During follow-up, patients were seen by a radiation oncologist
and head-and-neck surgeon every 3 months until 2 years after
CRT, and thereafter every 6 months until 5 years after CRT.
Imaging using CT or MRI was done in case of clinical suspicion
of recurrent disease.
Carboplatin Area Under the
Concentration–Time Curve
For patients who received carboplatin, the dose was calculated
retrospectively as area under the curve (AUC) for each cycle.
The Calvert formula was used: AUC = absolute dose (mg)
carboplatin/(creatinine clearance+ 25).
Statistical Analysis
Assuming a completion rate of 60% for cisplatin and a sampling
ratio of 1, we estimated that 353 patients had to be included
to demonstrate 10% difference in completion rate in favor of
carbo-5FU, with a type 1 error rate (alpha) of 5% and a power
of 0.80.
Pearson chi-square test and Mann–Whitney U-test were
used to compare variables between patient cohorts. Logistic
regression analysis was used to analyze the association between
chemotherapy completion and other variables. In the univariate
analyses all patient and tumor characteristics were included. For
the multivariate analyses only the factors that were significant in
univariate analysis were used.
In the univariate analysis, OS, DFS, LRC, and distant
metastasis–free interval were analyzed using the Kaplan–Meier
method and compared with the log-rank test. Hazard ratios
(HRs) were calculated with the Cox proportional hazards
model. In both Kaplan Meier and Cox regression analysis,
censoring was applied in case patients were lost to follow-up.
In the multivariable analysis, associations between clinical and
pathological parameters and OS were determined with Cox
proportional hazards model using the Wald statistic. In addition,
Cox regression provided an estimate of the effect of treatment
on OS and DFS after the adjustment for covariates modeling the
HR. In this way, we were able to investigate OS and DFS stratified
for chemotherapy regimen independently of the differences in
baseline characteristics.
Levene’s test was used to compare variances in AUC. To
determine if high carboplatin AUC during cycle one and two
resulted in omission of the third cycle, we used the Mann–
Whitney U test to compare the cumulative AUC dose of cycle
one plus cycle two between patients who completed three carbo-
FU cycles and patients who completed only two cycles. Statistical
tests were performed using SPSS (version 23.0 for Windows R©;
IBM, Armonk, NY, USA).
RESULTS
Demographics
A total of 434 patients were included, 211 of whom were in
the carbo-5FU cohort and 223 in the cisplatin cohort. From all
consecutive patients treated at the UMCG, 30 patients received
cetuximab and were therefore excluded from analysis. None of
the UMCG patients was treated with cisplatin. A total of 72
patients were excluded from the AUMC cohort based on either
receiving weekly cisplatin (n = 48) or cetuximab (n = 27)
(Supplementary Figure 1). Of the total group of patients, 74%
were men. The mean age at diagnosis was 57 years (range 29–73).
The most common tumor location was the oropharynx (64%).
Patient and tumor characteristics are listed in Table 1. Detailed
information on comorbidity in both study cohorts is shown in
Table 2. No significant differences between patients treated with
carbo-5FU and cisplatin were noted for sex, age, comorbidity,
tumor site, and stage. However, there were significant differences
between both study cohorts for the following variables: T and N
classification, p16 status, and tobacco exposure. Patients treated
with carbo-5FU had higher T and N classification and fewer p16-
positive oropharynx tumors and were more frequently current
smokers. Because no reliable data onWorld Health Organization
(WHO) performance score, mucositis, skin toxicity, and alcohol
consumption could be derived from patient records; these
variables could not be included in the analysis.
Treatment Compliance
Of the patients treated with carbo-5FU, 60.2% completed three
chemotherapy cycles vs. 76.7% of the patients treated with
cisplatin (p < 0.001). Only 4.4% of the patients in the carbo-
5FU cohort and 6.7% of the patients in the cisplatin cohort
had chemotherapy dose reductions (p = 0.3). The reasons for
discontinuation of chemotherapy are listed in Table 3.
Outcome
Themedian follow-up was 27months (range 1–109) in the carbo-
5FU cohort and 35 months (range 1–111) in the cisplatin cohort.
In the carbo-5FU cohort, 79 patients had died (37.4%), compared
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TABLE 1 | Baseline patient characteristics.
Carbo-5FU Cisplatin p
Characteristics (n = 211) (n = 233)
Age, years 0.605
[Median (IQR)] [58 (53–63)] [58 (52–63)]
Sex 0.186
Male 149 (70.6) 170 (76.2)
Female 62 (29.4) 53 (23.8)
Comorbidity 0.902
Yes 75 (35.3) 78 (35.0)
No 136 (64.5) 145 (65.0)
Tumor site 0.869
Oral cavity 14 (6.6) 25 (11.2)
Hypopharynx 30 (14.2) 38 (17.0)
Larynx 24 (11.4) 26 (11.7)
Oropharynx 143 (67.8) 134 (60.1)
T classification 0.002
T1 18 (8.5) 23 (10.3)
T2 39 (18.5) 49 (22.0)
T3 55 (26.1) 88 (39.5)
T4 99 (46.9) 63 (28.3)
N classification <0.001
N0 14 (6.6) 40 (17.9)
N1 17 (8.1) 42 (18.8)
N2 171 (81.0) 135 (60.5)
N3 9 (4.3) 6 (2.7)
AJCC stage 0.650
III 27 (12.8) 45 (20.2)
Iva 162 (76.8) 158 (70.9)
IVb 22 (10.4) 20 (9.0)
p16 (in oropharynx tumors) <0.001
Positive 65 (45.4) 85 (63.4)
Negative 73 (51.0) 39 (29.1)
Unknown 5 (3.5) 10 (7.5)
Tobacco exposure 0.565
Current smoker 138 (65.4) 97 (43.5)
Former smoker 53 (25.1) 82 (36.8)
Never smoked 20 (9.5) 44 (19.7)
Pack-years 0.262
Zero 20 (9.5) 44 (19.7)
<10 3 (1.4) 8 (3.6)
>10 167 (79.1) 143 (64.1)
Missing 21 (10.0) 28 (12.6)
Data are presented as No. (%) unless otherwise indicated. The Mann–Whitney U-test was
used. AJCC, American Joint Committee on Cancer (7th edition); IQR, interquartile range.
Tobacco exposure is defined as current/former smoker.
to 61 (27.4%) in the cisplatin cohort (Table 4). The cause of
death was tumor-related in 53 patients (25.1%) in the carbo-
5FU cohort and in 45 patients (20.2%) in the cisplatin cohort.
Treatment-related deaths were observed in 3 patients (1.4%) in
the carbo-5FU cohort (heart failure, sepsis, and sudden death)
and in 2 patients (0.9%) in the cisplatin cohort (pneumonia and
sudden death).
TABLE 2 | Baseline comorbidity in the carbo-5FU and in the cisplatin cohort.
Carbo-5FU Cisplatin pa
Characteristics (n = 211) (n = 233)
Comorbidity 0.902b
Myocardial infarction 18 19 1.00
Peripheral vascular disease 14 4 0.15
Diabetes mellitus 11 16 0.432
Pulmonary embolism 2 2 1.00
COPD 11 9 0.217
Cerebrovasculair accident/TIA 11 9 0.649
Other malignancyc 17 30 0.089
COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack.
aPearson chi square test was used unless otherwise indicated.
bMann–Whitney U-test was used.
cMalignancy in medical history.
TABLE 3 | Reasons for discontinuation of chemotherapy.
Carbo-5FU Cisplatin p
Reasonsa (n = 211) (n = 233)
Thrombocytopenia 52 (24.6) 1 (0.4) <0.001
Acute kidney injury 2 (0.9) 21 (9.4) <0.001
Leukocytopenia 19 (9.0) 6 (2.6) 0.005
Ototoxicity 0 (0) 8 (3.5) 0.005
Emesis 0 (0) 5 (2.2) 0.029
Performance 4 (1.9) 1 (0.4) 0.158
Patient request 5 (2.3) 2 (0.9) 0.223
Allergic reaction 2 (0.9) 0 (0) 0.145
Anemia 4 (1.9) 1 (0.4) 0.158
Other 11 (1.4) 8 (3.1) 0.408
Data presented as No. (%) unless otherwise indicated. The Mann–Whitney U-test
was used.
aOne or more reasons could be reported per patient.
Median OS was 65 months in the carbo-5FU cohort and
not reached in the cisplatin cohort. The risk of death was
higher in the carbo-5FU cohort (HR 1.53, 95% CI, 1.09–2.14,
p = 0.01). 1-year and 3-year OS was 86.7 and 65.5% for carbo-
5FU and 89.9% and 76.6% for cisplatin (Figure 1A). Univariate
analysis demonstrated that lower T-classification, lower N-
classification, p16 positivity (in oropharyngeal tumors), non-
smoking, cisplatin chemotherapy, and the absence of a second
primary tumor were associated with better OS (Table 5). Sex, age,
and tumor site were not associated with OS. Multivariate analysis
showed that lower T classification and lower N classification,
p16 positivity (in oropharyngeal tumors), and the absence of
second primaries were independently associated with better OS
(Table 5). Chemotherapy regimen (HR 1.08, 95% CI, 0.76–
1.55) and smoking (HR 1.20, 95% CI, 0.91–1.60) were not
independently associated with OS. Kaplan–Meier curves for OS
of both study cohorts and adjusted OS curves according to the
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Cox proportional hazards model (labeled with an asterisk) are
shown in Figure 1A.
Median DFS was not reached in either cohort. One-year
and 3-year DFS were 77.5 and 70.0% for carbo-5FU compared
to 84.5 and 78.6% for cisplatin (HR 1.37, 95% CI, 0.93–
2.01, p = 0.05, Figure 1B). Kaplan–Meier curves for DFS of
both study cohorts and adjusted DFS curves according to the
Cox proportional hazard model (labeled with an asterisk) are
shown in Figure 1B. Similar outcome was observed for both
LRC (HR 1.27, 95% CI, 0.74– 2.09, p = 0.4) and distant
metastasis-free interval (HR 1.08, 95% CI, 0.62–1.90, p = 0.77)
as presented in Figure 2.
TABLE 4 | Disease and survival status of patients at the time of analysis.
Carbo-5FU Cisplatin pa
n = 211 n = 233
Survival status 0.03
NED 128 (60.7) 155 (69.5)
AWD 4 (1.9) 7 (3.1)
DOD 52 (24.6) 44 (19.7)
DOC 26 (12.3) 17 (7.6)
Missing death 1 (0.5) 0 (0)
Event
Residual disease 13 (6.2) 5 (2.2) 0.041
Local regional recurrence 28 (13.3) 30 (13.5) 0.611
Distant metastasis 24 (11.3) 25 (11.2) 0.957
Local regional + distant metastasis 49 (23.2) 47 (21.1) 0.590
a Mann–Whitney U-test was used. NED, no evidence of disease; AWD, alive with disease;
DOD, died of disease; DOC, died of other cause.
In a combined analysis of the treatment groups, a trend
toward better OS in patients who completed three cycles of
chemotherapy compared to the patients who completed one or
two cycles of chemotherapy was observed (5-year OS 61.6 vs.
53.7%, HR 1.32, 95% CI, 0.92–1.89, p= 0.11); see Figure 3.
Treatment-Related Toxicity
Thrombocytopenia was the main reason for discontinuation
in the carbo-5FU cohort. Acute kidney injury followed by
ototoxicity was the most common reason for not completing
three cycles of cisplatin. The risk of discontinuation for
chemotherapy-associated toxicity was higher in the carbo-5FU
cohort than in the cisplatin cohort (relative risk = 1.69). There
was no difference in radiotherapy completion rate between study
cohorts: 97.7% for the carbo-5FU cohort vs. 95.5% for the
cisplatin cohort (p= 0.3). In multivariate analysis, chemotherapy
completion was negatively associated with carbo-5FU, female
sex, and comorbidity. No association between chemotherapy
completion rate and T classification, N classification, tumor
location, age, smoking status, or p16 status was found.
Grade 3 or 4 anemia was seen only in the carbo-5FU
cohort and occurred in 4.7% of the patients. Grade 3 or 4
thrombocytopenia was observed more frequently in the carbo-
5FU cohort compared to the cisplatin cohort (13.7 vs. 1.8%, p
< 0.001). Neutropenic fever was uncommon in both cohorts,
whereas leukopenia was frequently reported in both groups: in
15.6% of the patients in the carbo-5FU cohort and in 21.1% in
the cisplatin cohort (p = 0.430). Acute kidney injury grade 3–4
was observed only in the cisplatin cohort, in 13 patients (6 vs.
0%, p < 0.001). At 6–12 weeks after treatment, 7 of these patients
(3%) still had treatment-related kidney injury.
Almost 80% of the patients in the carbo-5FU cohort received
carboplatin, with an AUC between 4 and 6 (Figure 4). The
FIGURE 1 | (A) Overall survival stratified by chemotherapy regimen. (B) Disease-free survival stratified by chemotherapy regimen. The adjusted overall survival
estimation for both cohorts is labeled with an asterisk.
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mean AUC of the cycles received was <4.00 in 36 patients
(17%) and >7.00 in 8 patients (3.8%). Four of these 8 patients
could not continue therapy because of treatment-related toxicity.
Patients who completed three carbo-5FU cycles received a similar
cumulative carboplatin dose during the first two cycles [median
TABLE 5 | Significant Variables Univariate Analysis and Multivariate Analysis for
Overall Survival.
Variable HR 95% CI p
Univariate analysis
T-classification T1-T2 1(ref)
T3-T4 4.04 2.400–6.803 < 0.001
N-classification N0-N2a 1(ref)
N2bc-N3 1.83 1.244–2.700 0.002
p16 (in oropharynx tumors) 0.25 0.153–0.411 < 0.001
Second primarya 2.38 1.252–4.541 0.008
Treatment regimen 1.53 1.094–2.136 0.013
Tobacco exposure 1.30 1.779–1.669 0.041
Multivariate analysis
T-classification T1-T2 1(ref)
T3-T4 3.42 1.984–5.882 < 0.001
N-classification N0-N2a 1(ref)
N2bc-N3 2.23 1.464–3.380 < 0.001
p16 (in oropharynx tumors) 0.35 0.211–0.591 < 0.001
Second primarya 2.98 1.464–5.851 0.001
Treatment regimen 1.19 0.835–1.709 0.331
Tobacco exposure 1.15 0.859–1.538 0.349
Cox regression was used. (ref) denotes for reference variable. Tobacco exposure was
defined as current/former smoker or non-smoker.
aSecond primary in the Head and Neck region at time of initial diagnosis.
8.78, interquartile range (IQR) 7.90–9.75, min–max 3.28–12.40]
compared to patients that completed two carbo-5FU cycles
(median 8.71, IQR 7.84–9.74, min–max 4.52–13.83, p= 0.85). No
association was found between carboplatin dose and grade 3 or 4
thrombocytopenia, leukocytopenia, or anemia.
Extra Hospital Admissions
Patients treated with cisplatin were more likely to have extra
hospital admissions (57.4 vs. 18.5%, p < 0.001) during CRT,
mainly due to dehydration/acute kidney injury. The median
duration of unplanned admissions was 4 days in the cisplatin
FIGURE 3 | Overall survival stratified by chemotherapy completion.
FIGURE 2 | (A) Locoregional failure stratified by chemotherapy regimen. (B) Distant metastasis-free interval stratified by chemotherapy regimen.
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FIGURE 4 | Distribution of carboplatin AUC. Each vertical bar on the horizontal axis represents a chemotherapy cycle.
TABLE 6 | Reasons Extra Hospital Admission.
Carbo-5FU Cisplatin pa
n = 211 n = 233
Characteristics
Extra admission >0.001
One 39 (18.5) 128 (57.4)
Two 5 (2.4) 53 (23.8)
Duration of admission 0.171
[median(IQR)] [5(4–9)] [4(3–7)]
Reason for admission >0.001
Decreased renal function 0 (0) 79 (35.4)
Nausea and vomiting 6 (2.8) 44 (19.7)
Fever 22 (10.4) 14 (6.27)
Dehydration 1 (0.5) 15 (6.7)
Diminished performance 3 (1.4) 8 (3.1)
Infection 3 (1.4) 7 (2.7)
Tumor related 3 (1.4) 1 (0.4)
Other 6 (2.8) 13 (5.8)
aMann-Whitney U test was used. IQR, inter quartile range.
cohort, with an IQR of 4–9 (range 1–28) and 5 days in the
carbo-5FU cohort (IQR 3–7, range 1–60). Reasons for each extra
hospital admission are reported in Table 6.
DISCUSSION
The purpose of this study was to compare tolerability and efficacy
of concomitant CRT with carbo-5FU and concomitant CRT
with cisplatin in locally advanced HNSCC. We hypothesized
that carbo-5FU is better tolerated than cisplatin and therefore
results in a higher percentage of patients completing three
chemotherapy cycles with similar efficacy. However, the results
showed that patients in the carbo-5FU cohort were less likely
to complete three cycles of chemotherapy than patients in the
cisplatin cohort.
The observed completion rate of 76.8% in the cisplatin
cohort was higher than expected, and even higher than in two
randomized controlled trials, where one would expect selection
of fitter patients compared to our real-life data (7, 8). A factor
that might have influenced cisplatin completion rate is the
proportion of p16-positive oropharyngeal cancer patients, which
is rising over time. Since p16-positive oropharyngeal cancer
usually occurs in younger patients with a better performance
status, fewer smoking pack-years, and less comorbidity, it is
likely that these patients are more often capable of completing
three cycles. However, we found no association between p16
status and chemotherapy completion. Another factor could be
the rigorous supportive care given by specialized oncology nurse
practitioners. Vigorous hydration and frequent extra admissions
could possibly have led to higher chemotherapy compliance and
therefore should be taken into consideration for generalizability
of the results.
In a trial comparing CRT with carbo-5FU to RT alone for
stage III–IVB HNSCC, 65% of the patients completed three
cycles of chemotherapy (9). This is comparable to the completion
rate (60.2%) that we found. In our study, the reasons for not
completing chemotherapy differed between cohorts, with more
thrombocytopenia and leucopenia reported in the carbo-5FU
cohort and more kidney injury and ototoxicity in the cisplatin
cohort. This corresponds to the known toxicity profiles of
both platinum agents (9–11). In the carbo-5FU cohort, 24.6%
of the patients could not complete chemotherapy because of
thrombocytopenia. If the platelet count was <100 × 109/L on
day 22 or day 43, the cycle was postponed. This usually resulted
in omission of the third cycle because it could not be given within
the radiotherapy interval.
Although OS was significantly better in the cisplatin cohort,
the well-known prognostic factors were all advantageous for
this cohort. After correcting for T stage, N stage, p16 status,
and second primaries in multivariate analysis, we found that
treatment regimen was not an independent prognostic factor for
OS (12). Similar DFS, LRC, and distant metastasis–free interval
were observed in both univariate and multivariate analysis.
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Our results are similar to those of two previous comparative
studies that demonstrated no significant difference in outcome
between patients who received cisplatin and those who received
carbo-5FU (13, 14). However, these single-center retrospective
studies were restricted by statistical power and potential selection
bias (13, 14).
Furthermore, we investigated whether treatment delay due to
thrombocytopenia could have been caused by a relatively high
carboplatin dose because dosing was based on body surface area
rather than on creatinine clearance. However, we did not find
an association between carboplatin AUC and grade 3 or grade
4 thrombocytopenia. Neither did we find a difference between
cumulative carboplatin AUC of the first two cycles between
patients who completed three cycles and those who completed
two cycles.
Another interesting strategy that could reduce acute toxicity
of concomitant CRT and further increase compliance comes
from the Radiation Therapy Oncology Group 0129 trial. This
study demonstrated similar efficacy of two cycles of high-dose
cisplatin plus accelerated fractionation radiotherapy compared to
three cycles of cisplatin plus standard fractionation (15). In the
experimental arm, 87.8% of the patients completed two cycles
of cisplatin whereas in the standard arm 69.0% completed three
cycles. However, no difference in grade 3 or higher toxicity
was found.
A limitation of our study is a difference in baseline
characteristics between the cohorts due to the non-randomized
retrospective design. Although this difference does not affect
interpretation of chemotherapy completion rate, which was
associated with treatment regimen, sex, and comorbidity, it
does complicate interpretation of efficacy endpoints. However,
a future randomized controlled trial investigating carbo-5FU
vs. cisplatin is unlikely because the treatment focus has shifted
toward immunotherapy and treatment de-escalation for low-
risk p16-positive oropharyngeal cancer. Therefore, comparing
patient cohorts from two tertiary care centers in the same country
and geographic region with different institutional practice
provides the best level of evidence attainable in current clinical
practice. Another limitation of this study is that we were not able
to retrieve reliable information on performance status, mucositis,
skin toxicity, and alcohol consumption because this was not
registered systematically.
To our knowledge, this is the first well-powered retrospective
cohort study in which carbo-5FU and cisplatin as concomitant
CRT for locally advanced HNSCC are compared with regard to
chemotherapy completion. A lower chemotherapy completion
rate was found for patients treated with carbo-5FU compared to
patients treated with cisplatin. However, chemotherapy regimen
was not independently associated with OS. We therefore believe
that both chemotherapy regimens are viable treatment options
for concomitant CRT in patients with locally advanced HNSCC.
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